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Australian patients with lysosomal storage disorders who meet specific 
criteria receive enzyme replacement therapy (ERT) through the 
nationally administered Life Saving Drugs Program (LSDP) of the 
Commonwealth Department of Health and Ageing.[1] The Gaucher 
Disease Advisory Committee (GDAC) was a panel of medical experts 
appointed by the Department to advise on patient suitability for therapy, 
drug dosages and monitoring protocols. In June 2009, Genzyme 
Corporation, which manufactures imiglucerase (Cerezyme), the only 
ERT registered for the treatment of Gaucher disease in Australia at that 
time, announced that due to a viral contamination problem there would 
be no further shipments of imiglucerase to Australia prior to the end 
of 2009. On 11 August 2009, Genzyme further revised down its supply 
of Cerezyme to 20% of usual patient doses until the end of 2009. The 
GDAC allocated available drug supplies in order to maintain treatment 
to those patients most in need on a hierarchal clinical severity basis. 
A cohort of 24 type 1 Gaucher disease patients was withdrawn from 
therapy, 22 of whom had no discernible clinically significant adverse 
effects when reviewed off therapy for up to 6 months, as previously 
reported.[2] In January 2010, the 22 patients who had continued on the 
‘drug holiday’ were able to recommence therapy, generally at reduced 
doses, when imiglucerase supplies improved. In this paper, we review 
the course of 20 of the patients who have been on imiglucerase for 
periods of at least 24 months after the end of their drug holiday. Two of 
24 (8.5%) changed to another company’s ERT during the drug holiday, 
1/24 (4.25%) commenced substrate reduction therapy (SRT) due to 
problems with venous access and 1/24 (4.25%) moved overseas. It is 
reassuring that no patient has experienced an irreversible complication 
of their Gaucher disease, and over the 24-month period, most have 
shown return of their haematological and chitotriosidase levels to their 
stable ‘pre-drug holiday’ status and, in terms of skeletal parameters, 
most have stable magnetic resonance images (MRIs) that did not 
deteriorate over the period of the drug holiday.
Methods
Patients enrolled in the Australian government-funded ERT 
programme are required to sign a consent form permitting the 
collection of demographic, clinical and investigational data, their 
analysis by the GDAC and publication. All data analysis and 
publication are of de-identified information. All skeletal MRI 
scans are formally evaluated for bone marrow burden according 
to the scoring systems of Terk and Maas[3,4] by a single radiologist 
experienced in Gaucher disease imaging.[5]
Of the 24 type 1 Gaucher disease patients who were allocated 
to a drug holiday during the imiglucerase rationing period, two 
recommenced therapy with another company’s ERT, on a clinical 
trial, prior to the end of the 6 months due to a deterioration of their 
clinical state. In January 2010, 6 months after the start of the drug 
holiday, the 22 patients who had remained on the drug holiday were 
able to access therapy, generally at reduced doses, when imiglucerase 
supplies improved. Twenty patients have received imiglucerase for at 
least 24 months after the end of their drug holiday. Two of 24 (8.5%) 
changed to another company’s ERT, 1/24 (4.25%) commenced SRT 
due to problems with venous access and 1/24 (4.25%) moved overseas. 
For statistical analyses, time 0 was immediately before starting the 
drug holiday. For percentage calculations, the values of all parameters 
analysed are allocated a score of 100% at time 0.
Results
Of the 20 patients, 11 (55%) were female, their mean age was 38 
(range 18 - 77) years, they had been on imiglucerase ERT for a 
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In Australia, 58 patients with Gaucher disease were managed by a Gaucher Disease Advisory Committee (GDAC) through a centrally adminis-
tered national programme, the Life Savings Drug Program (LSDP). In June 2009, Genzyme Corporation, which manufactures imiglucerase 
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of at least 24 months after the end of their ‘drug holiday’. No patient experienced a bone crisis nor clinical nor magnetic resonance imaging 
evidence of new avascular necrosis events during this period. Two years after recommencing ERT after a 6-month drug holiday, no patient had 
developed an overt irreversible complication of their Gaucher disease, with the majority returning to their previous clinical status.
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mean of 9.2 (range 2 - 15) years. No patient 
developed a clinically detectable irreversible 
complication of their Gaucher disease up to 
2 years after recommencing ERT after their 
drug holiday.
Considering the 20 patients who recom-
menced imiglucerase therapy after the drug 
holiday and were reviewed over the ensuing 
24 months: their mean imiglucerase dose 
24 months after recommencing ERT was 
20.3 inter national units/kg/2 weeks (range 
15 - 30 inter national units/kg) compared 
with a mean dose of imiglucerase of 21.8 
international units/kg/2 weeks (range 15 - 33.6 
international units/kg) prior to withdrawal of 
therapy.
Haemoglobin concentrations were normal 
in all 20 patients (100%) when ERT was with-
drawn and remained in the normal range in all 
20 (100%) at 24 months after recommencing 
therapy following the drug holiday. After 
restarting ERT, the mean haemoglobin 
percentage at 12 months was 99% (range 92 - 
104%, n=20) and at 24 months 97.7% (range 
88 - 109%, n=20) of pre-ERT cessation values, 
as shown in Fig. 1. Platelet concentrations were 
in the normal range in 18 patients (18/24, 
75%) at the time of ERT cessation, remained 
in the normal range in 8/18 (44%) and became 
subnormal in 10/18 (56%) on the drug 
holiday. Considering the 20 patients followed 
up for 24 months: platelet concentrations 
were abnormally low in 12 patients (12/20, 
60%) at the end of the drug holiday period 
and remained in the abnormal range in 2/12 
(17%) and were in the normal range in 18/20 
(90%). After restarting ERT, the mean platelet 
percentage at 12 months was 89.7% (range 73 - 
127%, n=20), and at 24 months 99.7% (range 
83 - 113%, n=18) of pre-ERT cessation values, 
as shown in Fig. 2. Two patients had symptoms 
of easy bruising and no patient experienced a 
clinically significant bleed.
Chitotriosidase was monitored in 17/20 
(85%) patients, with 3/20 (15%) uninformative 
due to them being homozygous for the null 
mutations. Levels increased in all patients 
during their drug withdrawal; the mean 
chitotriosidase percentage increase at the end 
of the drug holiday was 443% (range 130 - 
1  231%, n=17). After restarting ERT the 
mean chitotriosidase percentage at 12 months 
was 239% (range 77 - 508%, n=17) and at 
24 months 97% (range 36 - 157%, n=16) of 
pre-ERT cessation values, as shown in Fig. 3.
We did not perform MRI studies 
specifically at either the time of cessation 
or restarting of therapy. The most recent 
MRI performed prior to cessation of therapy 
was, therefore, compared with the annual 
MRIs performed after restarting therapy. 
Twenty patients have had skeletal MRI 
follow-up ranging from 12 to 24 months after 
recommencement of therapy. At 12 months 
after recommencement of ERT, although 
4/20 (20%) showed possible progression of 
their bone marrow involvement on the basis 
of increases in their semi-quantitative bone 
marrow burden (BMB) scores, at 24 months 
16/17 (94%) showed stabilisation of their 
marrow involvement with no change from 
pre-drug holiday severity and 1/17 (6%) 
showed an improvement. None of the four 
patients showing possible progression of their 
bone marrow involvement on BMB scores at 
12 months had bone-related symptoms or any 
features of new irreversible skeletal lesions, 
such as due to avascular necrosis, and 1/4 
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Fig. 1. Individual patient serial haemoglobin levels. Baseline represents level of 100% at time 0 when 
drug holiday commenced.
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Fig. 2. Individual patient serial platelet counts. Baseline represents level of 100% at time 0 when drug 
holiday commenced.
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Fig. 3. Individual patient serial chitotriosidase levels. Baseline represents level of 100% at time 0 when 
drug holiday commenced.
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showed improvement at the 24-month study, while the other 3/4 have 
not yet had MRIs subsequent to the 12-month review.
Eight patients complained that their symptom of fatigue had returned, 
three during the drug holiday and five subsequently. After restarting 
ERT, two patients experienced a recurrence of nonspecific limb pain, 
which had previously resolved on ERT, requiring reinstitution of non-
steroidal anti-inflammatory therapy in one of them. These symptoms 
were also not associated with any clinical evidence of a new irreversible 
bone complication. No patient experienced any specific limb pain 
to suggest a Gaucher disease-related bone crisis. No patient showed 
an overt enlargement in liver or spleen size over the 24 months, as 
determined by clinical examination.
Discussion
These results suggest that it may be safe to withhold therapy in selected 
type 1 Gaucher disease patients who have initially been ‘debulked’ 
with ERT and show features of mild, stable disease. Continued and 
vigilant monitoring of such patients remains an essential part of the 
treatment regimen to prevent irreversible complications. Previous 
experience on the clinical stability of this cohort off ERT for up to 
6 months suggested that studies of maintenance therapy without a 
no-treatment arm may lead to erroneous conclusions.[2] Furthermore, 
some selected patients may, owing to specific circumstances such as 
overseas travel, have treatment holidays or delayed infusions without 
short-term adverse outcomes.
This cohort of patients will continue to be closely monitored to 
ensure that none has developed subclinical complications during 
their drug holiday that might predispose them to future irreversible 
complications. If no long-term adverse effects are seen, such patients, 
and others rationed to lower doses, could be considered for more 
flexible and personalised dosage regimens in future. Although 
reassuring that skeletal clinical and imaging studies have remained 
stable following the drug holiday, long-term investigation of measures 
of skeletal involvement are necessary to confirm that there will be no 
detrimental effects in terms of bone disease.
ERT for Gaucher disease is generally considered life-long, with 
most treatment protocols recommending bi-weekly intravenous 
infusions, inconvenient for both patients and healthcare providers. 
There are also attendant infusion-related risks.[6,7] Further analysis 
of a larger cohort of patients previously on drug holidays should 
facilitate the development of international criteria for defining 
stable patients[8] who could be suitable for receiving maintenance 
therapy with longer intervals between infusions and consideration of 
sanctioned treatment-free periods, such as during periods of overseas 
travel, with appropriate monitoring.
The difficulty in assessing disease load, developing ERT criteria 
regarding who to treat and when to start, and assessing optimal, 
personalised, dosage regimens for both initial management and 
maintenance therapy, reinforces the role of multidisciplinary 
specialist physician expertise in investigating and managing patients 
with rare inherited metabolic disorders. The results of this study also 
emphasise the importance of individualised ERT dosing for patients 
with type 1 Gaucher disease manifesting variable phenotypic effects.
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